The Definitive Peptide Research Reference Guide — Compound Review

Home Compounds BPC-157 TB-500 CJC-1295 Ipamorelin GLP-1 GHK-Cu Epithalon NAD+ Comparisons BPC-157 vs TB-500 Sermorelin vs Ipamorelin Semaglutide vs Tirzepatide Guides GHK-Cu Guide GHRH Analogues Ipamorelin Guide Peptide Reconstitution Guide Peptide Injection Sites Guide Peptide Storage Guide Semaglutide Dosage BPC-157 Dosage Research Guides Joint Pain Weight Loss Longevity Vendor Scoreboard All Vendor Comparisons Peptide Price Comparison Vendor Closures & Status How to Read a Peptide COA How to Vet a Peptide Vendor Why Purgo Labs Purgo Labs Review Purgo Labs Discount Code Where to Buy by Compound Legal Status Shop Purgo Labs

Semaglutide vs Tirzepatide

Semaglutide vs Tirzepatide: the two most clinically validated GLP-1 class compounds. Semaglutide is a pure GLP-1 agonist; tirzepatide is a dual GLP-1/GIP agonist. Head-to-head trials show tirzepatide produces greater weight loss.

Clinical Trial Comparison

Semaglutide (STEP-1): 14.9% weight loss at 68 weeks. Tirzepatide (SURMOUNT-1): 20.9% at 72 weeks. SURPASS-CVOT direct comparison: tirzepatide 10 mg showed 12.4% weight loss vs 8.4% for semaglutide 1 mg at 40 weeks.

Mechanism Difference

Semaglutide: GLP-1 receptor agonism only — appetite suppression, insulin secretion, gastric emptying delay. Tirzepatide: GLP-1 + GIP receptor agonism — the additional GIP component improves insulin sensitivity in adipose tissue and may reduce nausea.

Which to Choose for Research

Semaglutide: more clinical data, longer track record, lower cost, cardiovascular outcome data (SELECT trial). Tirzepatide: greater weight loss, potentially better tolerability due to GIP component, more recent approval. Both are appropriate for weight loss research.